How has treating infections changed with the availability of experimental vaccines and therapeutics, and how can we apply this to COVID-19 today?
April 2020
Outcomes in disseminated nocardiosis are variable and depend on patient factors.
Funded jurisdictions scramble to meet daunting deadlines yet maintain optimism that the new federal initiative can end flat funding and catalyze progress.
IDSA reached its goal, but nobody’s buying. Can the drowning antimicrobial pipeline be saved?
Infections caused by non–carbapenemase-producing carbapenem-resistant Enterobacteriaceae present challenges in the treatment paradigm. Given the limited clinical data, the preferred therapeutic approach remains unknown.
To better support the use of critical antibiotics, the Centers for Medicare & Medicaid Services revised the rules governing reimbursement for qualifying antibiotic products. For these changes to succeed, hospital systems will need to make adjustments.
With advancements in antiretroviral therapy, people with HIV are now living longer and developing age-related chronic conditions.
Interests have recently skewed toward the use of carbapenem-sparing regimens in light of growing selection for carbapenem-resistant organisms.
Christina Tan, MD, MPH, from the New Jersey Department of Health discusses COVID-19.
COVID-19 does not present our first pandemic, nor will it be our last. What should we take note of?
